Biosimilars for Retinal Diseases: Understanding the Phase 3 Clinical Trial Design
- 1 January 2022
- journal article
- editorial
- Published by Elsevier in Ophthalmology
- Vol. 129 (1) , 65-66
Abstract
No abstract availableFunding Information
- Genentech
- GlaxoSmithKline
- Research to Prevent Blindness
- Novartis
This publication has 4 references indexed in Scilit:
- Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular DegenerationOphthalmology, 2022
- Biosimilars for Retinal Diseases: An UpdateAmerican Journal of Ophthalmology, 2021
- Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2021
- Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspectiveBritish Journal of Ophthalmology, 2019